ClinicalTrials.gg
RecruitingNCT07618832Updated Jun 2, 2026

Graded Motor Imagery for Primary Dysmenorrhea

An interventional study of Graded Motor Imagery (GMI) and Sham Graded Motor Imagery in Primary Dysmenorrhea (PD), sponsored by Dr. Mehak Naeem. Recruiting at 1 site in Pakistan. Open to female participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Dr. Mehak Naeem · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Dysmenorrhea with a site in Pakistan — 10 open to participants now, 12 under way, none of them phase 3. Dysmenorrhea · Pakistan.

Planned enrollment
3rd of 29
81 · median 40
Started
2026
with 3 others
No phase
28 of 29
10 open now
Primary completion
2026-08
later than 8 of 11 live
Registered
23rd of 29
by date
Lead sponsor
1 of 29
Dr. Mehak Naeem

Among the 29 studies in Dysmenorrhea with a site in Pakistan, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2026, is one of 28 with no phase, reaches primary completion later than 8 of the 11 other live ones, and was the 23rd registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

10 of the 29 studies in Dysmenorrhea with a site in Pakistan are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 12 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 30 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Dysmenorrhea with a site in Pakistan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if graded motor imagery can reduce pain sensitivity and period pain in women with primary dysmenorrhea (painful periods with no medical cause).

The main questions it aims to answer are:

  1. Is there a decrease in pressure pain threshold (increased pain sensitivity) with graded motor imagery?
  2. Is the intensity of menstrual pain reduced by graded motor imagery?
  3. Is GMI helpful to reduce menstrual symptoms and pain catastrophizing (negative thinking about pain)?

Researchers will compare full GMI (active intervention), a sham GMI(inactive intervention), and a wait-list (no intervention) to see if GMI works better than the alternatives.

Participants will:

  1. Take part in a 6-week graded motor imagery program, sham program, or no intervention control.
  2. Do laterality recognition, motor imagery, and mirror therapy exercises in the graded motor imagery group.
  3. Complete pain and symptom assessments before and after the program, and again at follow-up.
Read the detailed description

Women with primary dysmenorrhea have decreased pressure pain threshold (PPT) at local abdominal and lumbar sites and at remote sites (tibialis anterior). This is indicative of central sensitization, rather than just peripheral, prostaglandin-driven pain. This sensitization extends out of the menstrual window and is associated with increased pain catastrophizing (a cognitive-affective amplifier of central pain processing). All of these factors contribute to primary dysmenorrhea being an appropriate target for brain-directed intervention.

Graded Motor Imagery (GMI) is a three-phase physiotherapy program aimed at restoring the normal representation of pain in the cortex and reducing movement-related threat appraisal. Phases progress from implicit motor imagery using left/right body-part recognition tasks, followed by explicit mental rehearsal of pain-free movement. The third phase involves mirror therapy with visual feedback of normal movement. This sequenced approach targets the two measurable mechanisms underlying central sensitization in dysmenorrhea: altered pressure pain sensitivity and elevated pain catastrophizing. GMI has proven to be effective in complex regional pain syndrome, phantom limb pain, and genito-pelvic pain. However, it has not been specifically tested in primary dysmenorrhea.

This three-arm randomized controlled trial compares full GMI, sham GMI, and a wait-list control over six weeks of online-delivered sessions. The sham program is identical to GMI in terms of therapist contact time and structure of sessions, but employs non-pelvic imagery content (to control for non-specific effects of attention and engagement). The outcome is measured at baseline, 6 and 10 weeks by a blinded assessor.

03

Conditions studied

  • Primary Dysmenorrhea (PD)

Browse trials for

Keywords

  • Graded Motor Imagery
  • Primary Dysmenorrhea
  • Primary dysmenorrhea and pressure pain threshold
  • Primary dysmenorrhea and altered pain sensitivity
  • Non-pharmacological intervention for primary dysmenorrhea
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female sex (aged 18-30 years)
  2. Diagnosis of primary dysmenorrhea confirmed by a physician (painful menstruation for ≥6 consecutive cycles, in the absence of identifiable pelvic pathology on clinical and/or ultrasound evaluation)
  3. Pain ≥4/10 NRS experienced during the last period.
  4. Confirmed altered pressure pain threshold: PPT ≥2 standard deviations below published norms for age-matched healthy women, measured at baseline assessment
  5. Regular menstrual cycle (21-35 days)
  6. Capable of engaging in virtual video sessions and taking online tests.
  7. Consent to withhold new analgesic or hormonal treatments during the study period.

Exclusion criteria

Exclusion Criteria:

  1. Secondary dysmenorrhea (endometriosis, adenomyosis, fibroids, pelvic inflammatory disease, ovarian cysts ≥3 cm confirmed on imaging)
  2. Current use of hormonal (which alter prostaglandin levels and pain processing)
  3. Pregnancy or lactation
  4. Concurrent chronic pain condition (fibromyalgia, CRPS, chronic low back pain, chronic pelvic pain unrelated to menstruation)
  5. Neurological or psychiatric disorder that would impair motor imagery ability (stroke, schizophrenia, active psychosis)
  6. Cognitive impairment affecting capacity
  7. Participation in another clinical trial within 4 weeks before enrollment
  8. Previous exposure to graded motor imagery or mirror therapy
  9. Regular use of NSAIDs or opioids for non-menstrual indications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
81 participants (estimated)

Study arms

  • Experimental
    Graded Motor Imagery Protocol

    Participants in this arm will be engaged in a 6-week graded motor imagery program, consisting of two supervised sessions per week and daily home practice. The intervention will have three phases: laterality recognition training with images of the pelvis and abdomen, explicit motor imagery of pain-free abdominal and pelvic movements, and mirror therapy/visual feedback with a mirror box to produce the illusion of normal and pain-free lower abdominal movement. A trained physiotherapist will deliver online sessions, and participants will complete about 15 minutes of home practice each day, which will be recorded in a diary.

    Behavioral: Graded Motor Imagery (GMI)

  • Sham comparator
    Sham Graded Motor Imagery

    Participants in the sham group will undergo a program of the same amount of contact time as well as duration over 6 weeks with the same number of sessions. The sham intervention will consist of three phases. Sham laterality discrimination tasks will be performed with distal body parts only (e.g., hands and feet) and without pelvic content. Moreover, the sham general relaxation imagery will have peaceful scenes rather than body movement. Lastly, sham mirror exposure will be done by looking at a mirror showing the contralateral hand but not at the pelvic area. The sham protocol aims to control non-specific effects of therapist contact, attention, and imagery engagement, and to remove the pelvic-specific cortical engagement as occurred in the active component of GMI.

    Behavioral: Sham Graded Motor Imagery

  • No intervention
    Wait-List Control

    Participants in the wait-list group will receive no intervention throughout the 10-week study. They will be given standard written information regarding menstrual health and will be allowed to use analgesics as needed, which will be noted as a covariate.

Interventions

  • BehavioralGraded Motor Imagery (GMI)

    The intervention will be a structured 6-week graded motor imagery program focused on the modulation of pain processing and sensorimotor representation in women with primary dysmenorrhea. It will consist of three sequential steps. Firstly, laterality recognition training with pelvic and abdominal body images. Secondly, explicit motor imagery with pain-free abdominal and pelvic movements. Finally, mirror therapy/visual feedback for normal pain-free movement. The program will be delivered online by a trained physiotherapist with two supervised sessions per week as well as daily home practice. This intervention is different from usual exercise or education because it mainly focuses on the cortical and sensorimotor mechanisms rather than only physical conditioning.

  • BehavioralSham Graded Motor Imagery

    The intervention will be a sham 6-week graded motor imagery program in which the participants will undergo a program of the same amount of contact time as well as duration over 6 weeks with the same number of sessions. The sham intervention will consist of three phases. Sham laterality discrimination tasks will be performed with distal body parts only (e.g., hands and feet) and without pelvic content. Moreover, the sham general relaxation imagery will have peaceful scenes rather than body movement. Lastly, sham mirror exposure will be done by looking at a mirror showing the contralateral hand but not at the pelvic area. The sham protocol aims to control non-specific effects of therapist contact, attention, and imagery engagement, and to remove the pelvic-specific cortical engagement as occurred in the active component of GMI.

06

What researchers measure

Primary outcomes

  1. Pain Pressure Threshold

    Pressure pain threshold will be measured at local abdominal and lumbar sites, and at a remote site over the tibialis anterior muscle by using a handheld algometer. Three readings will be taken at each site and averaged. Higher values will indicate lower pain sensitivity.

    Time frame: Baseline, post-intervention at 6 weeks, and 4-week follow-up.

  2. Menstrual pain intensity

    Menstrual pain intensity will be assessed using a Numeric Rating Scale during active menstruation. Participants will rate their pain on the days of menstrual pain, and the scores will be recorded for comparison over time. Higher scores will indicate greater pain intensity.

    Time frame: Baseline, 6 weeks post-intervention, and 4-week follow-up.

Secondary outcomes

  1. Menstrual symptom severity

    Menstrual symptom severity will be measured using the Moos Menstrual Distress Questionnaire. This questionnaire assesses the severity of physical and emotional symptoms related to menstruation. Higher scores indicate more severe menstrual symptoms.

    Time frame: Baseline, 6 weeks post-intervention, and 4-week follow-up.

  2. Pain Catastrophizing

    Pain catastrophizing will be measured using the Pain Catastrophizing Scale. This scale assesses exaggerated negative thoughts and feelings about pain. Higher scores indicate greater catastrophizing.

    Time frame: Baseline, 6 weeks post-intervention, and 4-week follow-up.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared owing to the confidentiality of study participants as well as the institutional restrictions. De-identified data may be available upon request to the corresponding author after getting institutional's approval.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2026, 4 months after the start.

Of 179 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 4 months is below that.

Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2026
First posted
Jun 1, 2026
StartActual
Apr 6, 2026
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07618832
Lead sponsor
Dr. Mehak Naeem
Collaborators
University of Health Sciences Lahore
Responsible party
Dr. Mehak Naeem (Principle Investigator, University of Health Sciences Lahore) — Sponsor-investigator
First posted
Jun 1, 2026
Start date
Apr 6, 2026
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Jun 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion